Abstract
Twenty effusions in sixteen patients with malignant peritoneal and/or pleural effusions were treated with intracavitary injection of lentinan. Lentinan was injected at a dosage of 4 mg/week for 4 weeks. In total, sixteen (80%) of twenty lesions demonstrated clinical responses. Performance status was improved in seven patients. The average survival time in responders was 129 days, while, in non-responders, it was 49 days. Serious toxicities were not observed.
NK activity of PBMC significantly decreased after lentinan injection. NK activity of PEC in responders was augmented significantly. Anti-Daudi and lymphokine activated killer activity were also augmented or maintained after lentinan injection.
Similar content being viewed by others
References
Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983; 357–64.
Yasumoto K, Miyazaki K, Nagashima A, Ishida T, Kuda T, Yano T, Sugimachi K, Nomoto K. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 47: 2184–7.
Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum. Caner Res 1983; 43: 1395–401.
Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from lentinus edodes (Berk.) Sing Nature 1963; 222: 687–8.
Chestermann H, Heywood R, Allen TR, Street AE, Edmondoson NA, Prentice DE. The intravenous toxicity of lentinan to the beagle dog. Toxicol Lett 1981; 9: 87–90.
Hamura J, Rollinghoff M, Wagner H. Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvantsof the b(1–3) glucan-type lentinan and its analogues. Immunology 1980; 39: 551–9.
Jeannin JF, Lagadec P, Pelletier H, Risser D, Olsson NO, Chihara G, Martin F. Regression induced by lentinan, of peritoneal carcinomatoses in a model of colon cancer in rat. Int J Immunopharmaco 1988; 10: 855–61.
Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Ito I, Ogawa N. End-point result of a randomized controlled study on the treatment of gastrointestinal cancer with a combination of lentinan and chemotherapeutic agents. In: Tsubura, E., Urushizaki, I. & Aoki, T., eds Rationale of biological response modifiers in cancer therapy Amsterdam: Excerpta Medica, 1985: 151–66.
WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization. Genova 1979.
Uchida A, Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. JNCI 1983; 71: 673–80.
Hamuro J, Chihara G. Lentinan, a T-cell-oriented immunopotentiator. Its experimental and clinical applications and possible mechanism of immune modulation. Immunomodulation agents and their mechanism (ed. Fenichel RL & Chirigos MA.) Marcel Dekker Inc., New York and Basel, 1984: 409–35.
Haba S, Hamaoka T, Takatsu K, Kitagawa M. Selective suppression of T-cell activity in tumor-bearing mice and its improvement by lentinan, a potent anti-tumor polysaccharide. Int. J. Cancer 1976; 18: 93–104.
Miyokoshi H, Aoki T. Acting mechanisms of lentinan in human-II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon inducer. Int J Immunopharmac 1984; 6: 373–9.
Herlyn D, Kaneko Y, Powe J, Aoki T, Koprowski H. Monoclonal antibody-dependent murine macrophage mediated cytotoxicity against human tumors is stimulated by lentinan. Jpn. J Cancer Res 1985; 76: 37–42.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oka, M., Yoshino, S., Hazama, S. et al. Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion. Biotherapy 5, 107–112 (1992). https://doi.org/10.1007/BF02171695
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02171695